NewslettersCell Therapy NewsUncategorizedUS FDA Approves New Label Update for CAR T-Cell Therapy Yescarta® Showing Prophylactic Steriod Use Improves Management of Cytokine Release SyndromeBy Justin.choi - January 31, 2022010Kite announced the FDA approved an update to the prescribing information for Yescarta® to include use of prophylactic corticosteroids across all approved indications.[Kite] 6445212 nan items 1 apa 0 default asc 1 171289 https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/Press Release